Healthcare Sector
Market Tracker
15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
| Expires | Type | Strike | OI | Change | Percent |
|---|---|---|---|---|---|
| 07/17/2026 | CALL | $125.00 | 16,908 | +3,791 | +28.90% |
| 10/16/2026 | CALL | $125.00 | 5,571 | +2,164 | +63.52% |
| 06/18/2026 | PUT | $120.00 | 1,158 | +86 | +8.02% |
| 06/18/2026 | CALL | $125.00 | 1,101 | +38 | +3.57% |
| 01/15/2027 | CALL | $125.00 | 112 | +35 | +45.45% |
| 01/15/2027 | PUT | $120.00 | 179 | +21 | +13.29% |
| 01/15/2027 | PUT | $160.00 | 0 | 0 | |
| 01/15/2027 | PUT | $165.00 | 0 | 0 | |
| 10/16/2026 | CALL | $105.00 | 4 | -1 | -20.00% |
| 06/18/2026 | CALL | $95.00 | 36 | -2 | -5.26% |
| 10/16/2026 | CALL | $110.00 | 16 | -3 | -15.79% |
| 06/18/2026 | CALL | $100.00 | 38 | -10 | -20.83% |
Contracts with largest changes in open interest from the previous trading day to the current/most recent.
| Name | Pct Held | Shares | Total |
|---|---|---|---|
| Fidelity Growth Company Fund | 2.79% | 1.43M | 59.8M |
| Vanguard Total Stock Market Index Fund | 1.63% | 838.65k | 35.06M |
| Fidelity Advisor Biotechnology Fund | 1.43% | 735.41k | 30.75M |
| Fidelity Small Cap Growth Fund | 1.08% | 555.73k | 23.23M |
| iShares Russell 2000 ETF | 0.86% | 443.24k | 18.53M |
| Fidelity Growth Company K6 Fund | 0.81% | 413.23k | 17.28M |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 0.80% | 410.03k | 17.14M |
| Fidelity Select Portfolios - Health Care | 0.75% | 382.53k | 15.99M |
| Vanguard Small-Cap Index Fund | 0.70% | 361.19k | 15.1M |
| Vanguard Extended Market Index Fund | 0.68% | 349.23k | 14.6M |
Nasdaq 100 Tumbles Over 3%, Marvell Crashes 12%: Stock Market Today
06/09 01:26 pm
Benzinga
Read moreGSK Makes Its Biggest Bet In More Than A Decade, Paying $10.6 Billion For Cancer Drug Developer Nuvalent
06/09 06:52 am
Benzinga
Read moreNon-Small Cell Lung Cancer Clinical Trial Race Intensifies as 100+ Companies Competing in Therapeutic Segment Worldwide | DelveInsight
04/16 01:00 pm
GlobeNewswire Inc.
Read moreThis Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally
03/16 08:00 pm
The Motley Fool
Read moreBiotech Fund Dumps $84 Million of Nuvalent With Stock Up 29%
02/23 11:01 am
The Motley Fool
Read moreWhat's Going On With Royalty Pharma Stock Wednesday?
12/31 11:47 am
Benzinga
Read moreNuvalent (NUVL) Q2 R&D Up 65%
08/07 08:18 am
The Motley Fool
Read moreNuvalent Stock Jumps On ESMO Data Presentation, Seeks To Raise $350M Via Equity
09/16 01:44 pm
Benzinga
Read moreWhy Earnings Season Could Be Great for Nuvalent (NUVL)
05/08 10:21 am
Zacks Investment Research
Read moreWhy Nuvalent Stock Tanked on Tuesday
10/17 06:27 pm
The Motley Fool
Read moreBenzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet
10/06 11:05 am
Benzinga
Read moreWhy Nuvalent Stock Skyrocketed 35% This Week
10/05 07:13 pm
The Motley Fool
Read moreWhere Nuvalent Stands With Analysts
10/05 12:00 pm
Benzinga
Read moreNuvalent (NUVL) Soars 36% on Upbeat Initial NSCLC Study Data
10/05 10:29 am
Zacks Investment Research
Read moreWhy Nuvalent Stock Was Soaring Wednesday
10/04 04:13 pm
The Motley Fool
Read moreChallenging Road Ahead for Cancer Drugs, Nuvalent Seeks to Break the Mold
09/27 02:44 pm
Benzinga
Read moreBenzinga's Top Ratings Upgrades, Downgrades For September 27, 2023
09/27 11:00 am
Benzinga
Read moreCanopy Growth, DocGo And Other Big Stocks Moving Lower On Monday
09/18 11:08 am
Benzinga
Read moreBenzinga's Top Ratings Upgrades, Downgrades For August 8, 2023
08/08 11:00 am
Benzinga
Read moreExpert Ratings for Nuvalent
08/08 10:00 am
Benzinga
Read moreBenzinga's Top Ratings Upgrades, Downgrades For July 24, 2023
07/24 11:00 am
Benzinga
Read moreRecent Price Trend in Nuvalent, Inc. (NUVL) is Your Friend, Here's Why
07/21 08:50 am
Zacks Investment Research
Read moreNuvalent, Inc. (NUVL) Is a Great Choice for 'Trend' Investors, Here's Why
06/07 08:50 am
Zacks Investment Research
Read moreBenzinga's Top Ratings Upgrades, Downgrades For January 18, 2023
01/18 11:00 am
Benzinga
Read moreAre Medical Stocks Lagging DICE Therapeutics (DICE) This Year?
01/02 10:40 am
Zacks Investment Research
Read moreHere's Why Momentum in Nuvalent, Inc. (NUVL) Should Keep going
12/02 09:50 am
Zacks Investment Research
Read moreWhat Makes Nuvalent, Inc. (NUVL) a Strong Momentum Stock: Buy Now?
11/17 01:00 pm
Zacks Investment Research
Read moreIs Genmab (GMAB) Outperforming Other Medical Stocks This Year?
11/08 10:40 am
Zacks Investment Research
Read more$21.8 Million Bet On Nuvalent? 4 Stocks Insiders Are Buying
11/08 07:30 am
Benzinga
Read more$7.8 Million Bet On Appian? 4 Stocks Insiders Are Buying
11/04 01:08 pm
Benzinga
Read moreTuSimple, Y-mAbs Therapeutics And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
10/31 08:08 am
Benzinga
Read moreNasdaq Climbs 275 Points; S&P 500 Rises Over 2%
10/28 02:35 pm
Benzinga
Read moreDow Jumps 600 Points; Crude Oil Down Over 1%
10/28 11:57 am
Benzinga
Read moreApple, Intel, And Some Other Big Stocks Moving Higher On Friday
10/28 10:55 am
Benzinga
Read moreUS Stocks Mostly Higher; Dow Surges 300 Points
10/28 10:27 am
Benzinga
Read moreThis Communication Services Stock Jumped 149%; Here Are 90 Biggest Movers From Friday
08/01 05:27 am
Benzinga
Read moreThe Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
11/10 09:19 am
Benzinga
Read moreWall Street Breakfast: What Moved Markets
09/25 07:56 am
Seeking Alpha
Read moreThe Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
09/14 07:50 am
Benzinga
Read moreThe Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod
09/08 07:32 am
Benzinga
Read moreThe Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab
09/02 08:19 am
Benzinga
Read moreThe Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering
09/01 07:32 am
Benzinga
Read moreThe Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration
08/27 07:35 am
Benzinga
Read moreThe Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO
08/26 08:09 am
Benzinga
Read moreThe Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug
08/25 07:30 am
Benzinga
Read more